Phase 1/2 Study of ISB 1442 in Relapsed/Refractory Multiple Myeloma
A Phase 1/2, First-in-Human, Multicenter, Open-Label, Dose Escalation and Dose-Expansion Study of Single-Agent ISB 1442 in Participants With Relapsed/Refractory Multiple Myeloma
Sponsor: Ichnos Sciences SA
Terminated
Business decision
Listed as NCT05427812, this PHASE1/PHASE2 trial focuses on Relapsed/Refractory Multiple Myeloma and remains terminated or withdrawn. Sponsored by Ichnos Sciences SA, it has been updated 7 times since 2022, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
7 versions recorded-
Sep 2025 — Present [monthly]
Terminated PHASE1/PHASE2
-
Feb 2025 — Sep 2025 [monthly]
Terminated PHASE1/PHASE2
Status: Recruiting → Terminated
-
Sep 2024 — Feb 2025 [monthly]
Recruiting PHASE1/PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Recruiting PHASE1/PHASE2
Phase: PHASE1_PHASE2 → PHASE1/PHASE2
-
Jul 2023 — Jul 2024 [monthly]
Recruiting PHASE1_PHASE2
▶ Show 2 earlier versions
-
Nov 2022 — Jul 2023 [monthly]
Recruiting PHASE1_PHASE2
Status: Not Yet Recruiting → Recruiting
-
Jul 2022 — Nov 2022 [monthly]
Not Yet Recruiting PHASE1_PHASE2
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Ichnos Sciences SA
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Bangalore, India , Benowa, Australia , Camperdown, Australia , Chicago, United States , Delhi, India , Detroit, United States , Fitzroy, Australia , Melbourne, Australia , Miami, United States , Milwaukee, United States and 4 more locations